Sanjay Kaeley, Head of Product Solutions, Commercial Training Solutions at L3Harris, drew our attention during WATS 2023 to another future-leaning part of the company’s portfolio – a prototype eVTOL training device.
In the phase 3 BOREAS study of patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation, patients treated with dupilumab experienced fewer COPD exacerbations, improved lung function, and improved quality of life compared with patients given a placebo.